Home/ Author / James Dunn
    Sort By
  • Newest

  • Newest

  • Oldest

  • Author Name

  • Author Name

  • David Chaplin

  • Drew Meredith

  • Giselle Roux

  • Greg Bright

  • Ishan Dan

  • James Dunn

  • Lachlan Maddock

  • Owen Raszkiewicz

  • All Categories

  • All Categories


  • IN Discussion

  • News

  • Leaders

  • Investing 101

  • Opinion

  • Uncategorized

  • Markets

  • ASX

  • Investing

James Dunn

Contributing Editor

James is Contributing Editor of the Inside Investor and Inside Adviser. James is a regular host of The Inside Network’s unique events and was founding editor of Shares magazine overseeing one of the most successful magazine launches in Australia. He has also written for BRW, Personal Investor, The Age and Management Today, and was subsequently personal investment editor at The Australian and editor of financial website, investorweb.com.au.

James Dunn results

ARK values Tesla in 2026 at US$4,600 a share

Cathie Wood, the chief investment officer, founder and head of ARK Invest, the specialist new-economy house, is often spoken of as the Warren Buffett of innovation, fintech, new tech and clean energy – despite a 60%-plus slump in the price of the firm’s flagship ARK Innovation ETF (NYSE Arca: ARKK) from its 2021 peak. But…

James Dunn | 20th Apr 2022 | More
One little prick that could go a long way

Blood diagnostic company Haemokinesis Limited is ASX-bound, with its $17 million share issue, at 20 cents a share, closing this Wednesday, with Haemokinesis expected to commence trading on the exchange on Friday, 8 April. When it hits the screens Haemokinesis will have a market capitalisation of $77 million. Haemokinesis – which means “moving blood with…

James Dunn | 18th Mar 2022 | More
Energy crisis an opportunity for ASX investors

What many people thought was a term from an economic history book, “energy crisis” has returned to the headlines, as rising global energy demand encounters restrictions on supply – and geo-political spot fires aplenty, with the Russia/Ukraine border a particular focus. In the old days, when people were familiar with the term “energy crisis,” there…

James Dunn | 2nd Feb 2022 | More
Beforepay does not pay for investors, after float

Everyone involved in the share market understands – or should understand – that pricing an initial public offering (IPO) is not an easy task. The underwriters or lead managers are trying to ascertain what the market will pay: they will test the marketability of the company by discreetly querying major investors on how much they…

James Dunn | 21st Jan 2022 | More
Super funds’ strong 2021 leaves COVID Crash in the rearview mirror

Australia’s super funds have posted a remarkable tenth consecutive calendar-year gain, with the median growth fund (having 61 per cent–80 per cent in growth assets) returning an impressive 13.4 per cent, according to the Zenith-owned research, data and analytics firm Chant West. The category is used as a proxy for the performance of super funds…

James Dunn | 21st Jan 2022 | More
  • Shipping coal, but doing it net-zero. Come again?

    Is this greenwashing, or simply a business trying to ensure that its operations are conducted as responsibly as possible? Dalrymple Bay Infrastructure Limited (ASX: DBI), which listed in December 2020, is a unique business; it operates a major infrastructure asset – the Dalrymple Bay Coal Terminal on the central Queensland coast – that ships coal…

    James Dunn | 15th Dec 2021 | More
    NAOS shows nouse in going private with new fund

    Specialist small- and micro-cap Australian equities investment manager NAOS Asset Management has taken its philosophy into the private markets, with the launch of its Private Opportunities Fund, for which it is seeking to raise at least $35 million. The fund will invest in up to 20 private companies that NAOS identifies as being profitable, having…

    James Dunn | 6th Oct 2021 | More
    Hunting the ten-bagger rock-kickers with Lowell

    The resources exploration-project development end of the Australian Securities Exchange (ASX) is an exciting place to spend time; one really gets a sense of how the share market kicked-off in Australia in the 1850s, when no boomtime goldfield town was complete without its own stock exchange. It is, potentially, the home of the multi-bagger –…

    James Dunn | 2nd Aug 2021 | More
    Self-Test the Start of Noxopharm’s Standout Story

    An essential part of developing a drug is the requirement for tests on human volunteers, usually starting in Phase 1. But for Noxopharm’s Veyonda drug, the first human volunteer was the company’s CEO and managing director, Dr. Graham Kelly. It was 2014, and some of the top cancer specialists in Australia had told Kelly that…

    James Dunn | 4th Jul 2021 | More
    Pharmaxis flicks the switch to self-funded trial program

    Sydney-based drug developer Pharmaxis (ASX:PXS) is moving through a pivot that the market is taking its time to understand, as it takes its lead drug candidate PXS‐5505 firstly through a Phase 1/2a trial for the treatment of the rare bone marrow cancer myelofibrosis, and secondly, into pre-clinical efficacy testing for glioblastoma (GBM), the most common form…

    James Dunn | 31st May 2021 | More
    1 2 3 10
    Our Authors
    What does High Conviction mean?
    Ishan Dan | 10th Mar 2021 | More
    Three ASX stocks ripe for a takeover
    Lachlan Buur-Jensen | 23rd Mar 2022 | More
    Battery materials in short supply but valuation is key
    Ishan Dan | 25th Mar 2022 | More
    Behind Brickworks’ (ASX:BKW) record profit
    Jaz Harrison | 25th Mar 2022 | More
    Is JB Hi-Fi the best retailer in Australia?
    Lachlan Buur-Jensen | 25th Mar 2022 | More
    Inside CSL’s big end of year deal
    Lachlan Buur-Jensen | 15th Dec 2021 | More